Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 866–867 | Cite as

ASO Author Reflections: Cytoreduction for Extrahepatic Metastatic Neuroendocrine Tumors

  • David L. Chan
  • Julie HalletEmail author
ASO Author Reflections



David L. Chan and Julie Hallet have no conflicts of interest to disclose.


  1. 1.
    Osborne DA, Zervos EE, Strosberg J, Strosberg J, Boe BA, Malafa M, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572–81.CrossRefGoogle Scholar
  2. 2.
    Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12:427–33.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Chan DL, Dixon M, Law CHL, Koujanian S, Beyfuss KA, Singh S et al. Outcomes of cytoreductive surgery for metastatic low-grade neuroendocrine tumors in the setting of extrahepatic metastases. Ann Surg Oncol. 2018;25:1768–74.CrossRefGoogle Scholar
  4. 4.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P et al. Whole-genome landscape of pancreatic neuroendocrine tumors. Nature. 2017;543(7643):65–71.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Susan Leslie Multidisciplinary Clinic for Neuroendocrine TumorsOdette Cancer CentreTorontoCanada
  2. 2.Division of Medical OncologySunnybrook Health Sciences CentreTorontoCanada
  3. 3.Department of SurgeryUniversity of TorontoTorontoCanada
  4. 4.Division of General SurgerySunnybrook Health Sciences CentreTorontoCanada
  5. 5.Sunnybrook Research InstituteTorontoCanada

Personalised recommendations